Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, whic...
Q1 2026
May 11, 2026
FY 2025
Mar 30, 2026
Q4 2025
Q3 2025
Nov 5, 2025
Q2 2025
Aug 14, 2025